Kiniksa Pharmaceuticals International, plc Deferred Federal Income Tax Expense (Benefit)
Kiniksa Pharmaceuticals International, plc (KNSA) reported Deferred Federal Income Tax Expense (Benefit) of $2.91 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredFederalIncomeTaxExpenseBenefit · last filed 2026-02-24
- Kiniksa Pharmaceuticals International, plc deferred federal income tax expense (benefit) for fiscal 2025 was $2.91M.
- Kiniksa Pharmaceuticals International, plc deferred federal income tax expense (benefit) for fiscal 2024 was -$1.91M.
| Period end | Deferred Federal Income Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | $2.91M 10-K · filed 2026-02-24 |
| 2024-12-31 | -$1.91M 10-K · filed 2026-02-24 |